Initiated 2026-09-22 · Price $72.47 (2026-09-21, stockanalysis.com) · Mkt cap $11.36bn · Health care / life-science tools · Model: verified (standalone / deal-break value only)

Rating: Sell — Conviction: High

Bio-Techne stopped being an equity on 2026-06-25. It is now a fixed-price cash claim: Merck KGaA has agreed to buy the company for $73.00 a share, the shareholder vote is set for 2026-09-23, German antitrust has cleared, and the stock closed at $72.47. What remains is a 0.73% gross spread to a late-2026/early-2027 close — roughly 2.0–2.7% annualized — against fed funds of 3.75–4.00%. An owner accepts a below-T-bill return while carrying full deal-break risk, and that risk is large: the stock was $58.87 the day before the announcement, and this model's standalone base case is well below even that. The business is fine; the security is a bond yielding less than cash with a 20-to-60-point left tail.

Model value range vs price
Bear $16.95Base $29.89Bull $47.10Price $72.47

Business overview

Bio-Techne sells the reagents, proteins, antibodies and assay instruments that biopharma, academic and clinical-research labs consume. Protein Sciences is 72% of FY2026 revenue ($874.6mm) at a 41.1% segment operating margin; Diagnostics & Spatial Biology is the other 28% ($336.4mm) at 11.2%. International is roughly 48% of sales, China included. Three things drive earnings: the research funding cycle (pharma R&D budgets, grants, and emerging-biotech venture financing — the swing factor), the consumables-versus-instruments mix, and margin recovery in the sub-scale D&SB segment. FY2026 revenue was flat at $1.215bn, organically and reported — a third straight year of no growth.

Bull case

  1. The end-market trough is behind it — Q4 FY2026 organic growth turned +3% (Protein Sciences +1%, D&SB +8%) against a flat year, consistent with instrument deferrals having bottomed. Plays out if biotech funding reopens as policy rates fall. Model: rev_growth
  2. Spatial biology and cell-therapy workflows scale — the fastest-growing segment is the lowest-margin one, so incremental volume there carries unusual operating leverage. Plays out if D&SB compounds high-single-digit on a fixed cost base. Model: rev_growth, ebitda_margin
  3. Margin mean-reversion — EBITDA margin was 36.0% in FY2022 and 28.7% in FY2026 on flat revenue; the gap is volume deleverage, not structural. Plays out if revenue grows at all. Model: ebitda_margin
  4. A strategic buyer has validated a far higher number — Merck KGaA is paying ~32.4x FY2026 EBITDA against 11.7–21.4x for listed peers. A second bidder, or renewed interest after a break, re-anchors the name. Model: exit_ev_ebitda

Bear case

  1. No growth is the base rate, not an aberration — revenue ran $1,105.6mm → $1,136.7mm → $1,159.1mm → $1,219.6mm → $1,215.0mm across FY2022–FY2026. Plays out if academic and emerging-biotech funding stays tight and China stays weak. Model: rev_growth
  2. Protein Sciences margin erodes while carrying the company — segment operating margin fell 42.6% → 41.1% in FY2026 on organic revenue of −1%. Plays out if mix keeps shifting toward the low-margin segment. Model: rev_growth, ebitda_margin
  3. Working capital absorbs the growth — receivables plus inventory less payables climbed from 27.3% of revenue in FY2022 to 31.7% in FY2026, so incremental revenue converts to cash poorly. Model: ebitda_margin, nwc_pct_rev
  4. At a 4.96% risk-free rate the standalone cash flows do not support the price — strict CAPM (beta 1.28, 5% ERP → 11.4% cost of equity) against a 2.3% FCF yield leaves a very wide gap. Plays out on any deal break. Model: wacc, exit_ev_ebitda

Valuation & balance sheet

Metric (definition) Current Own history (range or 5y avg) Peers Source, as-of
EV / EBITDA (TTM, EBITDA = GAAP op. income + D&A) 34.09x ~26.5x at the 2026-06-24 undisturbed close; deal struck at ~32.4x TMO 21.4x · DHR 17.3x · QGEN 11.7x stats / peers, 2026-09-22
FCF yield (TTM FCF / market cap) 2.32% 2.85% undisturbed n/a (unverified) stats / quote, 2026-09-22
Forward P/E 35.91x (deal-inflated) n/a (unverified) TMO 23.8x · DHR 21.6x · QGEN 15.7x stats / peers, 2026-09-22
Merger spread ($73.00 fixed cash vs market) 0.73% gross; ~2.0–2.7% annualized to a late-2026/early-2027 close n/a — deal signed 2026-06-25 Fed funds 3.75–4.00% merger / quote / macro_log, 2026-09-21

Model-implied value range (from model-summary.json; generic module, DCF-Gordon and DCF-exit-multiple, midpoints): Bear $16.95 · Base $29.89 · Bull $47.10 per share, i.e. implied returns of −76.6% / −58.8% / −35.0% vs $72.47. These ranges show how the bull and bear drivers translate into value; they are not price targets. Read them as deal-break recovery values, not a view on the $73.00 — modelling this name exists to size the downside leg of a binary payoff. The market price sits above even the bull case because it is not a fundamental price: it is the deal price minus a spread. Two anchors bound the break downside — this model's $17–47, and the undisturbed mark of $58.87 on 2026-06-24, itself −19% from here and the more generous of the two. The gap between them is almost entirely the discount rate: an 11.0% WACC implies an 8.5% terminal cap rate, while $58.87 implied a 2.85% FCF yield. The arithmetic does not depend on which is right — both sit well below $72.47.

Balance sheet: net cash. Net leverage −0.19x FY0 EBITDA ($200.0mm of debt against $264.7mm of cash), gross leverage 0.57x, coverage not meaningful, current ratio 4.55x; the $200.0mm drawn balance is placed in 2028 (analyst estimate — facility terms not retrieved); no agency ratings retrieved. Credit is a non-issue in every case; the balance sheet that matters is Merck KGaA's.

Model note: Built and LibreOffice-verified across all 3,188 formula cells; 0 failing error checks, 0 unverified inputs, 0 assumptions without a basis, no consistency CHECKs. It values the standalone business only and cannot express deal probability — do not read Base $29.89 as a target while the agreement is live. FY2026 is FY0 without normalisation, and FY2025 EBITDA ($212.2mm) is charge-depressed, so the history understates that year. Undrawn revolver capacity shows as zero because it was not disclosed, not because none exists. Generator note (2026-09-24): in this module share_change, capital_return_pct and cost_of_debt move EPS and the net-cash path only, and peer_pe feeds a cross-check only; none changes the value range, so bull/bear tags no longer cite them. Scenario deltas were rebuilt after multiple_pct shocks were extended to the Gordon method (previously they moved only the exit-multiple half), and EPS now uses average diluted shares.

Scenario stress test

Reasoned from the bull/bear drivers; the model column comes from the scenario overlays (Base + shock). Every row describes the standalone business — i.e. what a holder owns if the deal breaks in that regime. While the agreement holds, the traded price is pinned near $73.00 and near-insensitive to all of them; macro reaches this security only through completion risk and the spread's opportunity cost.

Scenario Effect Mechanism Magnitude Model Δ value vs Base ($/sh)
S1 Fast equity crash − Standalone multiple de-rates with quality growth; while the deal holds this name would sharply outperform, being a cash claim High −$4.94
S2 Slow bear / recession − Pharma R&D budgets and grant spending cut; instruments defer first, consumables follow — the exact FY2024–FY2026 pattern High −$4.31
S3 Rapid rate shock − Long-duration multiple compresses; separately widens the gap between the 0.73% spread and risk-free cash, the live risk to the traded price High −$6.08
S4 Slow rate grind − Same discount-rate channel, slower and across the full horizon Med −$3.62
S5 Soft-landing cuts + The best regime: falling rates reopen emerging-biotech funding, the marginal buyer of reagents, while the multiple re-rates High +$4.70
S6 Recession-driven cuts − Demand weakness outweighs discount-rate relief, but less than S2 because the cut supports the multiple Low −$0.84
S7a Credit liquidity shock − Small standalone effect on a net-cash balance sheet; the material channel is Merck KGaA's ability to raise the new debt funding an $11.3bn purchase — a completion risk, not a fundamental one Med −$1.83
S7b Slow default cycle − Financing window shuts for cash-burning small-cap biotech customers, who cut reagent and instrument orders first Med −$1.85
S8 Stagflation − Partial pricing power on proprietary reagents; grant-funded and reimbursed customers resist price, so margin gives ground and the discount rate does the rest High −$4.45
S9a Dollar spike − International is ~48% of revenue; translation drag on nearly half the base Med −$1.27
S9b Dollar slide + Translation tailwind on that same 48%; also makes the USD price cheaper for a euro-functional acquirer, marginally supporting completion Low +$1.04
S10 Melt-up + Standalone multiple expands with the complex — though a fixed-price cash deal means the traded price would badly lag a melt-up High +$4.66
S11 Energy supply shock − Cold-chain freight and petrochemical-derived consumable inputs on a globally distributed reagent business; no demand channel Low −$0.71
S12 Mega-cap/AI derating − Not an AI name, and a rotation out of mega-cap tech partly favours it, but it still carries a high-multiple growth label Low −$0.91

Magnitude labels re-ranked 2026-09-25 to match the model's dollar deltas (skill 3a-v-b item 7; the 2026-09-24 generator fix enlarged multiple-shock rows): S7b Low→Med, S10 Med→High, S1 Med→High.

Currently active/on watch per the playbook: S3 partially active (price-level leg no longer met at a 4.96% 10Y as of 2026-09-21); S8, S10 and S11 on watch.

Model value change vs Base, by scenario
S3 Rapid rate shock−$6.08S1 Fast equity crash−$4.94S8 Stagflation−$4.45S2 Slow bear / recession−$4.31S4 Slow rate grind−$3.62S7b Slow default cycle−$1.85S7a Credit liquidity shock−$1.83S9a Dollar spike−$1.27S12 Mega-cap/AI derating−$0.91S6 Recession-driven cuts−$0.84S11 Energy supply shock−$0.71S9b Dollar slide+$1.04S10 Melt-up+$4.66S5 Soft-landing cuts+$4.70

What would change the call

Upgrades if: the merger terminates and the stock resets to where the standalone Base case implies a positive return, and organic growth confirms the Q4 FY2026 inflection (two straight quarters above 4%); or a competing bid above $73.00 turns the payoff from a spread into an option; or the spread widens enough to clear the T-bill yield by a wide margin without completion odds deteriorating. Downgrades if: already Sell — conviction deepens on an HSR second request, an in-depth regulatory review, or doubt about Merck KGaA's financing, in any case without the price adjusting to compensate.

Watch items

Sources